Daniel Agroskin, managing director at JLL Partners. Photo courtesy of the firm.
JLL closed its seventh fund at $1 bln in April 2016
New York sponsor looks to invest early in underlooked themes
Recent exits in pharma services: Patheon, BioClinica
Daniel Agroskin is a managing director at JLL Partners, where he leads the New York private equity firm’s healthcare efforts and is a member of the management committee. How would you describe JLL’s broader approach to healthcare investing? The way ...